NEW YORK (360Dx) – Biofortuna, a UK-based contract in vitro diagnostics development, freeze drying, and stabilization services provider, announced this week a new investment into and an expansion of its IVD service portfolio. The expansion will allow the firm to place a greater focus on immunoassay design, development, and manufacturing. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.